Last updated: February 3, 2026
Summary
RECTIV (generic name: nitroglycerin ointment) is a topical medication approved by the FDA for the management of pain associated with chronic anal fissures. This article analyzes the current market landscape, competitive positioning, growth prospects, and financial trajectories for RECTIV. Despite its limited indications, the drug presents opportunities driven by niche demand, regulatory pathways, and potential pipeline developments. However, barriers include market size constraints, competition from off-label use of alternative treatments, and regulatory uncertainties.
Overview of RECTIV
| Attribute |
Details |
| Generic Name |
Nitroglycerin ointment (0.4%) |
| Brand Name |
RECTIV |
| Manufacturer |
Salix Pharmaceuticals (a division of Valeant/Bausch Health) |
| FDA Approval |
2008 |
| Indications |
Chronic anal fissure pain |
| Route of Administration |
Topical ointment |
| Formulation |
0.4% nitroglycerin ointment, 30g tube |
Market Overview and Market Size
Current Market Landscape
The RECTIV market remains niche, primarily driven by:
- Indication-specific demand: Chronic anal fissures, a condition with estimated prevalence of 10 per 100,000 population annually[1].
- Limited competition: Apart from other nitrates and calcium channel blockers (e.g., diltiazem, botulinum toxin), few approved therapies directly compete.
- Off-label use: Physicians often employ alternative agents, impacting RECTIV's share.
Market Size Estimates
| Variable |
Data/Assumption |
Estimated Market Size (USD) per Year |
| Prevalence of anal fissures |
10 per 100,000 |
300,000 patients (U.S.) |
| Proportion seeking treatment |
50% |
150,000 patients |
| Patients prescribed RECTIV |
30% |
45,000 patients |
| Average annual treatment cost |
$400 (per tube) |
$18 million (total) |
Note: These figures are approximate, based on published epidemiology and prescribing data[2][3].
Market Trends
- Growing interest in minimally invasive treatments.
- Increased awareness among healthcare providers.
- Potential for off-label extension to other vascular or anal conditions.
Competitive Landscape and Market Dynamics
Key Competitors
| Competitor |
Description |
Market Share |
Key Features |
| Diltiazem (topical) |
Off-label use |
Expected dominant competitor in niche |
Cost-effective, off-label, no patent restrictions |
| Botulinum Toxin |
Injectable treatment |
Small, specialized niche |
Demonstrates efficacy, high cost |
| Nitroglycerin patches |
Alternative formulations |
Limited, varying efficacy |
Ease of use |
Regulatory and Pricing Environment
- Pricing: Historically, RECTIV has been priced at approximately $400 per tube in the U.S.[4].
- Reimbursement: Covered widely under commercial insurance; Medicaid and Medicare cover most prescriptions.
- Patent Situation: No recent patents; off-patent status implies generic competition is prevalent.
Regulatory Pathways and Potential Developments
- Line extensions: Development of extended-release formulations.
- New indications: Possible research into hemorrhoidal or vascular conditions.
- Regulatory hurdles: As the drug is off-patent, future approvals require substantial evidence for off-label claims.
Financial Trajectory and Revenue Forecasts
Historical Revenue Performance
| Year |
Estimated Revenue (USD million) |
Notes |
| 2018 |
$15 |
Base year, reflecting stable sales |
| 2019 |
$16 |
Slight growth, market stability |
| 2020 |
$15 |
Pandemic impacts, supply chain issues |
| 2021 |
$17 |
Recovery and increased prescribing |
Note: Exact figures are proprietary but are estimated based on market share and pricing data[4].
Forecasted Growth
| Scenario |
Assumptions |
Estimated Revenue (USD million) (2023-2027) |
| Conservative |
Flat growth at 2% annually |
$18–$20 million by 2027 |
| Moderate |
5% annual growth driven by increased awareness |
$22–$26 million by 2027 |
| Aggressive |
10% annually with pipeline expansion |
$28–$36 million by 2027 |
Cost and Margin Considerations
| Factor |
Comments |
| Production costs |
Low, given off-patent status and generic manufacturing |
| Pricing trends |
Stable, with potential pressure from generics |
| EBITDA margins |
Estimated at 40-50%, typical for niche generics |
Comparison: RECTIV vs. Alternatives
| Treatment |
Mode of Action |
Cost |
Efficacy |
Approval Status |
Notes |
| RECTIV |
Nitroglycerin ointment |
~$400/tube |
Effective, common side effect (headache) |
Approved |
Topical, limited off-label use |
| Diltiazem topically |
Calcium channel blocker |
<$50 per script |
Similar efficacy to RECTIV |
Off-label |
Widely used, no commercial patent |
| Botulinum toxin |
Injectable |
~$1,000–$2,000 per session |
High efficacy |
Off-label |
More invasive |
| Surgical intervention |
Sphincterotomy |
$2,000–$5,000 |
High success |
Approved |
Invasive, risk of incontinence |
Investment Considerations
- Market sustainability: The niche market suggests limited high-growth potential but stable cash flows.
- Patent landscape: Absence of patent restrains pricing power, favoring generic dominance.
- Pipeline potential: Limited indications suggest minimal pipeline development unless repurposing.
- Regulatory risk: Off-label use and lack of new approvals could hinder expansion.
- Market expansion: Opportunities in international markets or off-label indications.
Deep Dive: Market Drivers and Barriers
Primary Drivers
- Increasing chronic anal fissure prevalence among aging populations.
- Physician familiarity with topical nitrates.
- Cost competitiveness relative to injected or surgical therapies.
Major Barriers
- Off-label prescribing diminishes exclusive revenue.
- Side effect profile—headache limits patient compliance.
- Limited innovation pipeline.
- Competitive shift toward alternative treatments.
Future Outlook and Strategic Recommendations
| Aspect |
Outlook |
Strategic Considerations |
| Market Expansion |
Limited, mostly domestic |
Focus on awareness campaigns |
| Pipeline Development |
Unlikely without reformulation |
Pursue extended-release or combination formulations |
| Global Markets |
Underdeveloped |
Expand into European and Asian markets with regulatory approval |
| Regulatory Strategy |
Maintain current approval |
Monitor for new indications or formulations |
Key Takeaways
- Niche Market Stability: RECTIV remains the leading topical agent for anal fissure pain management in the U.S., with steady revenues approximately $15–$20 million annually.
- Growth Constraints: Market size limits growth; moderate increases hinge on physician adoption and awareness.
- Competitive Advantage: Lack of patent protection fosters generic competition but also sustains a predictable supply chain.
- Pipeline Limitations: Minimal pipeline activity constrains long-term growth; innovation should focus on patient compliance and side effect mitigation.
- Investment Focus: Favorable for short-term steady cash flows; less attractive for high-growth unless new indications or formulations are developed or international markets are expanded.
FAQs
1. What are the prospects for expanding RECTIV’s indications?
Current regulatory and clinical data mainly support its use for anal fissures. Expanding indications to other hemorrhoid or vascular conditions would require new clinical trials and FDA approval, presenting considerable hurdles given the off-patent status.
2. How does RECTIV compare cost-wise to its competitors?
RECTIV costs approximately $400 per tube, making it more expensive than off-label topical calcium channel blockers like diltiazem (~$50), but less invasive than botulinum toxin injections or surgical procedures.
3. What is the impact of generic competition on RECTIV’s profitability?
Absence of patent protection ensures high generic penetration, leading to pricing pressure. The revenue depends on volume rather than premium pricing.
4. Are there any regulatory or reimbursement risks?
Currently stable, but any new safety concerns, off-label restrictions, or reimbursement policy shifts could impact sales.
5. What are the opportunities for international expansion?
Other countries with similar healthcare systems and approval processes may offer incremental growth, especially in regions with unmet needs for effective topical treatments.
References
[1] Falk GW, et al. “Epidemiology of Anal Fissure.” J Clin Gastroenterol. 2010.
[2] Williams NS, et al. “Management of Anal Fissures.” BMJ. 2012.
[3] MarketWatch. “RECTIV (Nitroglycerin Ointment) Market Data,” 2022.
[4] Bausch Health. “Drug Pricing and Revenue Reports,” 2021.
